Ixekizumab effective psoriasis treatment through 60 weeksResults from three phase 3 trials, suggest ixekizumab (Talz, Eli Lilly & Company) is effective through 60 weeks of treatment among patients with moderate-to-severe plaque psoriasis.
New research focuses on B lymphocytes in psoriasisResearchers at the University of Würzburg in Bavaria, Germany, are focusing their psoriasis research on a cell type that has received little attention in connection with the skin disease: B lymphocytes.
Insurers make prescribing biologics difficultA new study suggests that insurance coverage of biologics for psoriasis is becoming more challenging. The need for prior authorization is increasing, as are the average time from prior authorization submission to coverage decisions and prior authorization denial rates.
Making strides in support for psoriasis patientsThe National Psoriasis Foundation seeks support for initiatives that will provide better access for psoriasis patients to effectively treat their disease.
Review examines psoriasis, smoking linkA recent paper sheds light on the relationship between smoking and psoriasis. Results offer a whole scenario related to the impact of smoking on psoriasis.
Payers want more dataA pioneering summit between healthcare payers and groups pursuing standardized outcome measures in dermatology has revealed that payers want outcome measures that are published, universally accepted and practical both for clinicians and payers.
Diet, skin disease data growingA growing number of studies suggest diet influences general skin health and specific skin diseases, from acne and eczema to skin aging. Dermatologists share their best practices for using diet to combat skin disease and promote skin health.
Pediatric psoriasis prognosis, management insightsRelationships between pediatric psoriasis and streptococcal infection, obesity, and genetics are discussed for their relevance to patient care.
Common questions about biologicsMark Lebwohl, M.D., reviews evidence pertaining to malignancy risks with biologics and the rationale for avoiding “drug holidays”.